• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Mannatech Reports Fourth Quarter 2024 Financial Results

    3/26/25 6:00:00 AM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $MTEX alert in real time by email

    Mannatech, Incorporated (NASDAQ: MTEX), a global health and wellness company committed to transforming lives to make a better world, today announced financial results for its fourth quarter of 2024.

    Quarter End Results

    Fourth quarter net sales for 2024 were $29.0 million, a decrease of $3.7 million, or 11.3%, as compared to $32.7 million in the fourth quarter of 2023. During the fourth quarter, the company's net sales declined 9.2% on a Constant dollar basis (a Non-GAAP financial measure); unfavorable foreign exchange during the fourth quarter caused a decrease of $0.7 million in net sales as compared to the fourth quarter of 2023.

    Gross profit as a percentage of net sales improved to 80.5% for the three months ended December 31, 2024, as compared to 75.4% for the same period in 2023.

    Commissions as a percentage of net sales were 40.6% for the three months ended December 31, 2024, as compared to 39.6% for the same period in the prior year. Incentive costs as a percentage of net sales were 1.0% for the three months ended December 31, 2024, as compared to 1.4% for the same period in 2023.

    For the three months ended December 31, 2024, overall selling and administrative expenses decreased by $1.7 million to $10.4 million, as compared to $12.1 million for the same period in 2023. The decrease in selling and administrative expenses consisted primarily of a $0.9 million decrease in payroll related costs, a $0.7 million decrease in marketing costs and a $0.1 million decrease in travel and entertainment costs.

    Fourth quarter operating income for 2024 was $0.9 million as compared to an operating loss of $0.9 million for the fourth quarter of 2023.

    Fourth quarter net income was $2.3 million, or $1.20 per diluted share, for the fourth quarter 2024, as compared to a net loss of $1.8 million, or $0.94 per diluted share, for the fourth quarter 2023.

    The approximate number of new and continuing independent associate and preferred customer positions held by individuals in Mannatech's network and associated with purchases of its packs or products as of December 31, 2024 and 2023 was approximately 133,000 and 145,000, respectively. Recruiting decreased 19.5% in the fourth quarter of 2024 as compared to the fourth quarter of 2023. The number of new independent associate and preferred customer positions in the company's network for the fourth quarter of 2024 was 14,615 as compared to 18,156 in 2023.

    Year End Results

    Net sales for 2024 was $117.9 million, a decrease of $14.1 million, or 10.7%, as compared to $132.0 million in 2023. During 2024, fluctuations in foreign currency exchange rates had an overall unfavorable impact on its net sales. During 2024, the company's net sales declined 8.6% on a Constant dollar basis (a Non-GAAP financial measure); unfavorable foreign exchange during 2024 caused a decrease of $2.7 million in net sales as compared to 2023.

    Gross profit as a percentage of net sales decreased to 77.6% for 2024, as compared to 78.0% for 2023 largely due to increased costs related to supply chain challenges, including increased product costs and increased freight costs.

    Commissions as a percentage of net sales were 39.2% for the year ending December 31, 2024 and 38.6% for the same period in the prior year. The costs of incentives, as a percentage of net sales decreased to 1.8% for the year ended December 31, 2024, as compared to 2.0% for the same period in 2023.

    For the years ended December 31, 2024 and 2023, overall selling and administrative expenses were $41.7 million and $50.2 million, respectively. The decrease of $8.5 million primarily includes a $3.2 million decrease in payroll related costs, $1.6 million decrease in legal and consulting fees, $1.5 million decrease in marketing costs, $0.6 million decrease in miscellaneous operating expenses, $0.5 million decrease in travel and entertainment costs, $0.5 million decrease in office expenses, $0.4 million decrease in credit card fees and $0.2 million decrease in contract labor costs.

    Operating income was $1.4 million in 2024 as compared to an operating loss of $1.0 million in 2023.

    For the year ended December 31, 2024, the company's tax provision was $1.3 million due to the company recording valuation allowance on losses in certain jurisdictions driven by changes in expected earnings mix between jurisdictions. During 2023, the company's tax provision was $1.1 million due to a mix of earnings across jurisdictions and the associated valuation allowance recorded on losses in certain jurisdictions.

    Net income for 2024 was $2.5 million, or $1.32 per diluted share, as compared to net loss of $2.2 million, or $1.20 per diluted share, for 2023.

    As of December 31, 2024, the company's cash and cash equivalents increased to $11.4 million from $7.7 million as of December 31, 2023.

    Landen Fredrick, President and CEO, acknowledged that "2024 was a challenging year for Mannatech, particularly in the Asia/Pacific region, due to persistent economic challenges. However, through strict cost management, we were able to achieve a positive net income. We remain dedicated to expanding our revenue and carefully managing our expenses moving forward."

    Non-GAAP Measures

    In addition to results presented in accordance with GAAP, this press release and related tables include certain non-GAAP financial measures, including a presentation of constant dollar measures. The company discloses operating results that have been adjusted to exclude the impact of changes due to the translation of foreign currencies into U.S. dollars, including changes in: Net Sales, Gross Profit, and Income from Operations.

    The company believes that these non-GAAP financial measures provide useful information to investors because they are an indicator of the strength and performance of ongoing business operations. The constant currency figures are financial measures used by management to provide investors with an additional perspective on trends. Although it believes the non-GAAP financial measures enhance investors' understanding of their business and performance, these non-GAAP financial measures should not be considered an exclusive alternative to accompanying GAAP financial measures. Please see the accompanying table entitled "Non-GAAP Financial Measures" for a reconciliation of these non-GAAP financial measures.

    Safe Harbor statement

    This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by use of phrases or terminology such as "may," "will," "should," "hope," "could," "would," "expects," "plans," "intends," "anticipates," "believes," "estimates," "approximates," "predicts," "projects," "potential," and "continues" or other similar words or the negative of such terminology. Similarly, descriptions of Mannatech's objectives, strategies, plans, goals or targets contained herein are also considered forward-looking statements. Mannatech believes this release should be read in conjunction with all of its filings with the United States Securities and Exchange Commission and cautions its readers that these forward-looking statements are subject to certain events, risks, uncertainties, and other factors. Some of these factors include, among others, Mannatech's inability to attract and retain associates and members, increases in competition, litigation, regulatory changes, and its planned growth into new international markets. Although Mannatech believes that the expectations, statements, and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its latest Annual Report on Form 10-K, and other filings filed with the United States Securities and Exchange Commission, including its current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.

    ^ Mannatech operates in China under a cross-border e-commerce platform that is separate from its network marketing model.

    Individuals interested in Mannatech's products or in exploring its business opportunity can learn more at Mannatech.com.

    MANNATECH, INCORPORATED AND SUBSIDIARIES

    CONSOLIDATED BALANCE SHEETS

    (in thousands, except share information)

     

     

    December 31, 2024

     

    December 31, 2023

    ASSETS

     

     

     

    Cash and cash equivalents

    $

    11,396

     

     

    $

    7,731

     

    Restricted cash

     

    550

     

     

     

    938

     

    Accounts receivable, net of allowance of credit losses of $935 and $1,278 in 2024 and 2023, respectively

     

    19

     

     

     

    91

     

    Income tax receivable

     

    737

     

     

     

    465

     

    Inventories, net

     

    10,405

     

     

     

    14,535

     

    Prepaid expenses and other current assets

     

    1,755

     

     

     

    1,774

     

    Deferred commissions

     

    1,259

     

     

     

    2,130

     

    Total current assets

     

    26,121

     

     

     

    27,664

     

    Property and equipment, net

     

    2,858

     

     

     

    4,147

     

    Operating lease right-of-use assets

     

    2,094

     

     

     

    3,315

     

    Other assets

     

    2,644

     

     

     

    3,751

     

    Deferred tax assets, net

     

    1,770

     

     

     

    1,611

     

    Long-term restricted cash

     

    569

     

     

     

    718

     

    Total assets

    $

    36,056

     

     

    $

    41,206

     

    LIABILITIES AND SHAREHOLDERS' EQUITY

     

     

     

    Commissions and incentives payable

    $

    8,642

     

     

    $

    8,175

     

    Accrued expenses

     

    3,832

     

     

     

    5,119

     

    Deferred revenue

     

    3,027

     

     

     

    4,786

     

    Accounts payable

     

    2,070

     

     

     

    4,010

     

    Current portion of operating lease liabilities

     

    1,178

     

     

     

    1,660

     

    Taxes payable

     

    1,788

     

     

     

    1,521

     

    Current notes payable

     

    84

     

     

     

    240

     

    Current portion of finance lease liabilities

     

    275

     

     

     

    269

     

    Total current liabilities

     

    20,896

     

     

     

    25,780

     

    Long-term notes payable, excluding current portion

     

    2,900

     

     

     

    —

     

    Operating lease liabilities, excluding current portion

     

    1,576

     

     

     

    2,582

     

    Other long-term liabilities

     

    1,390

     

     

     

    1,404

     

    Finance lease liabilities, excluding current portion

     

    680

     

     

     

    956

     

    Total liabilities

     

    27,442

     

     

     

    30,722

     

    Commitments and contingencies (Note 12)

     

     

     

    Shareholders' equity:

     

     

     

    Preferred stock, $0.01 par value, 1,000,000 shares authorized, no shares issued or outstanding

     

    —

     

     

     

    —

     

    Common stock, $0.0001 par value, 99,000,000 shares authorized, 2,742,857 shares issued and 1,884,814 shares outstanding as of December 31, 2024 and 2,742,857 shares issued and 1,860,154 shares outstanding as of December 31, 2023

     

    —

     

     

     

    —

     

    Additional paid-in capital

     

    33,027

     

     

     

    33,309

     

    Retained earnings (accumulated deficit)

     

    1,189

     

     

     

    (1,301

    )

    Accumulated other comprehensive loss

     

    (5,666

    )

     

     

    (1,015

    )

    Treasury stock, at average cost, 858,043 shares as of December 31, 2024 and 882,703 shares as of December 31, 2023

     

    (19,936

    )

     

     

    (20,509

    )

    Total shareholders' equity

     

    8,614

     

     

     

    10,484

     

    Total liabilities and shareholders' equity

    $

    36,056

     

     

    $

    41,206

    MANNATECH, INCORPORATED AND SUBSIDIARIES

    CONSOLIDATED STATEMENTS OF OPERATIONS

    (in thousands, except per share information)

     

     

    For the three months ended

    December 31,

     

    For the years ended

    December 31,

     

     

    2024

     

     

     

    2023

     

     

     

    2024

     

     

     

    2023

     

    Net sales

    $

    29,007

     

     

    $

    32,694

     

     

    $

    117,866

     

     

    $

    131,955

     

    Cost of sales

     

    5,643

     

     

     

    8,048

     

     

     

    26,406

     

     

     

    29,090

     

    Gross profit

     

    23,364

     

     

     

    24,646

     

     

     

    91,460

     

     

     

    102,865

     

    Operating expenses:

     

     

     

     

     

     

     

    Commissions and incentives

     

    12,072

     

     

     

    13,389

     

     

     

    48,309

     

     

     

    53,588

     

    Selling and administrative expenses

     

    10,428

     

     

     

    12,152

     

     

     

    41,722

     

     

     

    50,241

     

    Total operating expenses

     

    22,500

     

     

     

    25,541

     

     

     

    90,031

     

     

     

    103,829

     

    Income (loss) from operations

     

    864

     

     

     

    (895

    )

     

     

    1,429

     

     

     

    (964

    )

    Interest (expense) income, net

     

    (83

    )

     

     

    7

     

     

     

    (279

    )

     

     

    4

     

    Other income (expense), net

     

    2,095

     

     

     

    (973

    )

     

     

    2,590

     

     

     

    (170

    )

    Income (loss) before income taxes

     

    2,876

     

     

     

    (1,861

    )

     

     

    3,740

     

     

     

    (1,130

    )

    Income tax (provision) benefit

     

    (614

    )

     

     

    105

     

     

     

    (1,250

    )

     

     

    (1,109

    )

    Net income (loss)

    $

    2,262

     

     

    $

    (1,756

    )

     

    $

    2,490

     

     

    $

    (2,239

    )

    Income (loss) per common share:

     

     

     

     

     

     

     

    Basic

    $

    1.20

     

     

    $

    (0.94

    )

     

    $

    1.32

     

     

    $

    (1.20

    )

    Diluted

    $

    1.20

     

     

    $

    (0.94

    )

     

    $

    1.32

     

     

    $

    (1.20

    )

    Weighted-average common shares outstanding:

     

     

     

     

     

     

     

    Basic

     

    1,885

     

     

     

    1,860

     

     

     

    1,885

     

     

     

    1,866

     

    Diluted

     

    1,885

     

     

     

    1,860

     

     

     

    1,885

     

     

     

    1,866

     

    Non-GAAP Financial Measures (Sales, Gross Profit and Income From Operations in Constant Dollars)

    To supplement its financial results presented in accordance with generally accepted accounting principles in the United States ("GAAP"), Mannatech discloses operating results that have been adjusted to exclude the impact of changes due to the translation of foreign currencies into U.S. dollars, including changes in: Net Sales, Gross Profit, and Income from Operations. It refers to these adjusted financial measures as constant dollar items, which are non-GAAP financial measures. The company believes these measures provide investors with an additional perspective on trends. To exclude the impact of changes due to the translation of foreign currencies into U.S. dollars, it calculates current year results and prior year results at a constant exchange rate, which is the prior year's rate. The currency impact is determined by the difference between actual growth rates and constant currency growth rates.

    The table below reconciles fourth quarter 2024 constant dollar sales to GAAP sales.

     

    Sales - Q4 2024

     

     

    GAAP

    Measure:

    Total $

     

    Non-GAAP

    Measure:

    Constant $

     

    Constant $

    Change

     

    Americas

    $

    9.3

     

    $

    9.4

     

    $

    0.1

     

     

    Asia Pacific

    $

    17.4

     

    $

    18.1

     

     

    0.7

     

     

    EMEA

    $

    2.3

     

    $

    2.2

     

     

    (0.1

    )

     

    Total

    $

    29.0

     

    $

    29.7

     

    $

    0.7

     

     

    The table below reconciles fiscal year 2024 and 2023 constant dollar net sales, gross profit and income from operations to GAAP net sales, gross profit and income from operations.

     

    2024

     

     

    2023

     

     

    Constant Dollar Change

     

    GAAP

    Measure:

    Total $

     

    Non-GAAP Measure:

    Constant $

     

    GAAP

    Measure:

    Total $

     

    Dollar

     

    Percent

    Net sales

    117.9

     

    120.6

     

    $

    132.0

     

     

    (11.4

    )

     

    (8.6

    )%

    Gross profit

    91.5

     

    93.7

     

     

    102.9

     

     

    (9.2

    )

     

    (8.9

    )%

    Income (loss) from operations

    1.4

     

    2.2

     

     

    (1.0

    )

     

    3.2

     

     

    (320.0

    )%

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250326495457/en/

    Erin K. Barta

    General Counsel and Corporate Secretary

    214-724-3378

    [email protected]

    www.mannatech.com

    Get the next $MTEX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MTEX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MTEX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Mannatech Premieres Powerful New Documentary on Marathon Legend Steve Edwards

      "The Long Run" showcases a world-record journey powered by Glycan Replenishment Therapy and unmatched determination. Global health and wellness innovator Mannatech is proud to premiere Steve Edwards: The Long Run, an 11-minute short documentary chronicling the unbelievable true story of Steve Edwards—an everyday man turned endurance icon. With over 1,000 official marathons completed in record-setting average times, Edwards' legacy is one of resilience, quiet determination and the pursuit of human potential. The film debuts globally today, May 21, and is followed by an in-depth interview with Steve Edwards himself following the documentary. It is available to watch free at events.mannatech.

      5/21/25 12:16:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Reports Financial Results for First Quarter 2025

      Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its first quarter of 2025. First Quarter Highlights Net sales for the quarter ended March 31, 2025 were $26.6 million, as compared to $29.4 million for the same period in 2024, a decrease of $2.8 million, or 9.6%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $1.6 million, or 5.4%, and unfavorable foreign exchange caused a $1.2 million decrease in GAAP net sales as compared to the same period in 2024. The decline in revenues was principally due to slowing dem

      5/13/25 6:06:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Reports Fourth Quarter 2024 Financial Results

      Mannatech, Incorporated (NASDAQ: MTEX), a global health and wellness company committed to transforming lives to make a better world, today announced financial results for its fourth quarter of 2024. Quarter End Results Fourth quarter net sales for 2024 were $29.0 million, a decrease of $3.7 million, or 11.3%, as compared to $32.7 million in the fourth quarter of 2023. During the fourth quarter, the company's net sales declined 9.2% on a Constant dollar basis (a Non-GAAP financial measure); unfavorable foreign exchange during the fourth quarter caused a decrease of $0.7 million in net sales as compared to the fourth quarter of 2023. Gross profit as a percentage of net sales improved to 80

      3/26/25 6:00:00 AM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care

    $MTEX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Rameson Tyler bought $126,232 worth of shares (16,288 units at $7.75), increasing direct ownership by 6% to 299,197 units (SEC Form 4)

      4 - MANNATECH INC (0001056358) (Issuer)

      9/10/24 5:45:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care

    $MTEX
    SEC Filings

    See more
    • Mannatech Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - MANNATECH INC (0001056358) (Filer)

      5/13/25 5:06:07 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 10-Q filed by Mannatech Incorporated

      10-Q - MANNATECH INC (0001056358) (Filer)

      5/13/25 4:57:24 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form DEF 14A filed by Mannatech Incorporated

      DEF 14A - MANNATECH INC (0001056358) (Filer)

      4/22/25 5:01:03 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care

    $MTEX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form 4 filed by Director Toth Robert

      4/A - MANNATECH INC (0001056358) (Issuer)

      3/17/25 1:23:48 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Fredrick J Stanley was granted 2,686 units of Common Stock Par Value $0.0001 Per Share, increasing direct ownership by 0.76% to 356,975 units (SEC Form 4)

      4 - MANNATECH INC (0001056358) (Issuer)

      1/6/25 12:37:18 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Toth Robert was granted 2,686 units of Common Stock Par Value $0.0001 Per Share, increasing direct ownership by 3% to 91,130 units (SEC Form 4)

      4 - MANNATECH INC (0001056358) (Issuer)

      1/6/25 12:37:07 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care

    $MTEX
    Financials

    Live finance-specific insights

    See more
    • Mannatech Reports Financial Results for First Quarter 2025

      Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its first quarter of 2025. First Quarter Highlights Net sales for the quarter ended March 31, 2025 were $26.6 million, as compared to $29.4 million for the same period in 2024, a decrease of $2.8 million, or 9.6%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $1.6 million, or 5.4%, and unfavorable foreign exchange caused a $1.2 million decrease in GAAP net sales as compared to the same period in 2024. The decline in revenues was principally due to slowing dem

      5/13/25 6:06:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Reports Financial Results for Third Quarter 2024

      Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its third quarter of 2024. Third Quarter Highlights Net sales for the quarter ended September 30, 2024 were $31.7 million, as compared to $32.6 million for the same period in 2023, a decrease of $0.9 million, or 2.5%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $0.4 million, or 1.2%, and unfavorable foreign exchange caused a $0.5 million decrease in GAAP net sales as compared to the same period in 2023. The decline in revenues was principally due to slowi

      11/12/24 4:48:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Reports Financial Results for Second Quarter 2024

      Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its second quarter of 2024. Second Quarter Highlights Net sales for the quarter ended June 30, 2024 were $27.7 million, as compared to $32.6 million for the same period in 2023, a decrease of $4.9 million, or 14.9%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $4.2 million, or 12.9%, and unfavorable foreign exchange caused a $0.7 million decrease in GAAP net sales as compared to the same period in 2023. The decline in revenues was principally due to supply

      8/13/24 5:00:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care

    $MTEX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Mannatech Incorporated

      SC 13G - MANNATECH INC (0001056358) (Subject)

      11/1/24 11:44:29 AM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Mannatech Incorporated (Amendment)

      SC 13G/A - MANNATECH INC (0001056358) (Subject)

      1/13/23 11:03:46 AM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Mannatech Incorporated (Amendment)

      SC 13G/A - MANNATECH INC (0001056358) (Subject)

      2/7/22 6:32:28 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care

    $MTEX
    Leadership Updates

    Live Leadership Updates

    See more
    • Mannatech Announces Appointment of Robert A. Toth as Vice Chairman of the Board of Directors

      Mannatech, Incorporated (NASDAQ: MTEX) announced that on November 20, 2024, the Board of Directors of Mannatech, Incorporated (the "Board") appointed Robert A. Toth to the Board where he will serve as Vice Chairman of the Board of Mannatech, Incorporated (the "Company") effective December 1, 2024. Mr. Toth will serve as a Class III director of the Board. Mr. Toth previously served on the Company's Board between March 2008 through May 31, 2023. Mr. Toth previously served as the Chairman of the Compensation and Stock Option Plan Committee, served on the Audit Committee, the Nominating/Governance and Compliance Committee, the Science and Marketing Committee, and from August 2014 to March 201

      11/26/24 4:30:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Announces Appointment of James Clavijo as Chief Financial Officer

      Mannatech, Incorporated (NASDAQ: MTEX) announced that the Board of Directors appointed James Clavijo as Chief Financial Officer of Mannatech Incorporated (the "Company") effective July 1, 2024. James Clavijo brings over 25 years of experience in executive, finance, and accounting activities. He has served as CFO for biotech, medical technology, and pharmaceutical companies, including Longeveron (NASDAQ:LVGN), Guided Therapeutics (OTC:GTHP), Aeterna Zentaris (NASDAQ:AEZS), and Tri-source Pharma. Mr. Clavijo has led and advised companies with strategic plans for pharmaceutical commercialization and manufacturing, has negotiated licensing and drug development agreements, and he has advised c

      7/1/24 5:46:00 PM ET
      $AEZS
      $MTEX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medicinal Chemicals and Botanical Products
    • Mannatech Announces Retirement of Alfredo Bala and Promotion of Landen Fredrick to President and CEO

      Mannatech, Incorporated (NASDAQ: MTEX) reported that Alfredo (Al) Bala, announced his retirement as the company's CEO effective April 1, 2024. J. Stanley Fredrick, Chairman of the Board of Mannatech, Incorporated stated, "Al will continue to serve the company as an advisor focused on customer acquisition and sales growth. This transition enables Al to work more closely with our associates in the field which has always been his first love. In this new role, Al will also focus on field and leadership development, leveraging his 43 years of experience in direct sales at both the field and corporate level helping to create and develop programs dedicated to growing people and sales." Mr. Fredr

      3/13/24 7:30:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care